PATENT CLAIM ANALYSIS

Application Number: 15928811
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["424", "138100"]

Abstract:
We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.

Claim (Index 27):
The method of  claim 25 , wherein the biological agent is an antibody or antibody derivative, and wherein the antibody or antibody derivative preferentially or specifically binds to the mutant IDH2 enzyme over the wild type IDH2 enzyme.

Metadata:
- Claim Count in Document: 81.0
- Percentile: 90.0
- Lexical Diversity: 1.37736
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13060191', '14102730', '15589615', '15238161', '13452136']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8103362300720809
- 35 USC 102 Novelty (BERT): 0.6233313422730797
- Combined Prediction Score: 0.7916357412921808
- Mean Citation Score: 533.3740280000002
- Max Citation Score: 798.6665
- Similarity Product: 503.3271724665165

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test